EpiEndo

Reykjavik, IS · 1 known investors

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for chronic respiratory diseases such as COPD, based on research into macrolides and their effects on the lung epithelium. Its lead program, EP395 (glasmacinal), is a non-antibacterial macrolide with anti-inflammatory activity that is Phase 2b ready.